Navigation Links
Parenteral Depots Offer $8 Billion of Reformulation Opportunities and a Strong Competitive Edge in Crowded Pharmaceutical Space

FALLS CHURCH, Va., Feb. 14, 2011 /PRNewswire/ -- Technology Catalysts International (TCI), leading global consultants to the pharmaceutical industry, announced that research on trends and development in drug delivery have identified parenteral depots as key to reformulation of existing drugs with limited patent life, a different pathway for new drug development, and potential to offer a biosimilar product a competitive edge in a crowded pharmaceutical field.

In general, biopharmaceuticals are precluded from oral administration due to their size and susceptibility to degradation within the GI tract.  Consequently, most biopharmaceuticals are administered by injection, often multiple times per week.  Novel drug delivery systems such as depots, not only provide much needed relief to the patient in the form of less frequent injections but also offer biosimilar products a competitive edge over traditional dosage forms.

Technology Catalysts' newly-released report on "Parenteral Depot Technologies" identifies 35 companies actively developing parenteral depots categorized by polymer approach, branded/ generic products in development, and delivery vehicles that are open to licensing or other strategic alliance opportunities.  In addition, major depot-related activity within large and specialty pharmaceutical companies is discussed along with an overview of technologies to achieve sustained drug release for periods extending several months and at the same time, overcoming challenges such as premature drug degradation.

Dhiraj Chopra, Manager, R&D (Drug Delivery) for Bharat Serum & Vaccines, India states that parenteral depot injections are seen as having one of the greatest potentials in battling cancer and that Bharat has been very successful with their launch of leuprolide depot in India.  Besides leuprolide, the company has an impressive development effort under way for risperidone, octreotide, triptorelin, goserelin, leuprorelin, lanreotide, that could position Bharat as a global leader in depot injections and implants.  "Bharat is seeking potential business partners who offer complementary advantages for depot injection projects in Europe and the US," advises Dhiraj.

TCI's report also includes a market analysis of injectable depot technologies, sales of leading depot products in 2009, worldwide market growth from 2005-2009, market share by therapeutic category, role of generic chemicals and peptides, and product pipelines. Technology Catalysts forecasts the total parenteral depot market could approach nearly $8 billion by 2014.To download a complimentary excerpt of this report, go to:

About Technology Catalysts International:

Technology Catalysts International ("TCI") was founded in 1979 and provides consulting services in technology transfer and business research. The company specializes in technology licensing, technology assessment, and business intelligence. With a focus on pharmaceuticals, drug delivery, consumer healthcare, and advanced materials/processes, TCI's core consulting services are based on continuous monitoring of technological product development activities on a global basis.  TCI is headquartered in the US and has offices in the UK, Germany, Czech Republic, China, Korea, Japan, India, and Latin America.Contact:Ajay Rastogi, Vice PresidentTechnology Catalysts InternationalTelephone (703) 531-0257arastogi@technology-catalysts.com

SOURCE Technology Catalysts International
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Bioengineered veins offer new hope on horizon for patients lacking healthy veins for coronary bypass surgery or dialysis
2. Bionovo Announces Closing of Follow-on Offering of Common Stock and Warrants
3. Leading Scientific Laboratory Offers New Methods for Metals Testing
4. Spherix Announces Closing of Registered Direct Offering of $2.77 Million in Common Stock and Warrants
5. Ardea Biosciences Prices Public Offering of Common Stock
6. Investigational Compound Offers Novel Anti-IGF Approach To Inhibit Growth of Cancer Cells
7. Amarin Announces Proposed Public Offering of American Depositary Shares
8. Biotech Guru G. Steven Burrill Offers his Predictions on What Lies Ahead for the Biotech Industry in 2011
9. HRC Medical Center Offers Patients Relief with Innovative Bio-Identical Hormone Replacement Therapy
10. YM BioSciences Closes Public Offering of Common Shares
Post Your Comments:
(Date:11/25/2015)... PUNE, India , November 26, 2015 /PRNewswire/ ... The Global Biobanking Market 2016 - 2020 ... biobanks by maintaining integrity and quality in long-term ... and enabling long-term cost-effectiveness. Automation minimizes manual errors ... improves the technical efficiency. Further, it plays a ...
(Date:11/25/2015)... 2 nouvelles études permettent d ... différences entre les souches bactériennes retrouvées dans la plaque ... humains . Ces recherches  ouvrent une nouvelle ... charge efficace de l,un des problèmes de santé ... .    --> 2 nouvelles études permettent d ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. 25, ... HART ), a biotechnology company developing bioengineered organ ... Jim McGorry will present at the LD Micro ... at 2:30 p.m. PT. The presentation will be webcast ... days. Management will also be available at the conference ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... its business and prospects remain fundamentally strong and ... (zoptarelin doxorubicin) recently received DSMB recommendation to continue ... following review of the final interim efficacy and ... Primary Endpoint in men with heavily pretreated castration- ...
Breaking Biology Technology:
(Date:11/17/2015)... November 17, 2015 Paris ... --> Paris from 17 th ... the biometrics innovation leader, has invented the first combined scanner ... the same scanning surface. Until now two different scanners were ... scanner can capture both on the same surface. This ...
(Date:11/12/2015)... BOSTON , Nov. 12, 2015  A golden ... for Duchenne muscular dystrophy (DMD) has provided a new ... Boston Children,s Hospital, the Broad Institute of MIT and ... Brazil . Cell, ... some dogs "escape" the disease,s effects. The Boston Children,s ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
Breaking Biology News(10 mins):